NanoVibronix Inc
NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increa… Read more
Market Cap & Net Worth: NanoVibronix Inc (NAOV)
NanoVibronix Inc (NASDAQ:NAOV) has a market capitalization of $4.46 Million ($4.46 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31749 globally and #10458 in its home market, demonstrating a 0.24% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NanoVibronix Inc's stock price $4.10 by its total outstanding shares 1088192 (1.09 Million).
NanoVibronix Inc Market Cap History: 2015 to 2025
NanoVibronix Inc's market capitalization history from 2015 to 2025. Data shows change from $105.77 Million to $4.46 Million (-26.12% CAGR).
Index Memberships
NanoVibronix Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.00% | #815 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.00% | #2589 of 3165 |
Weight: NanoVibronix Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
NanoVibronix Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NanoVibronix Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.25x
NanoVibronix Inc's market cap is 0.25 times its annual revenue
0.67x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $105.77 Million | $147.00K | -$2.88 Million | 719.54x | N/A |
| 2016 | $129.71 Million | $229.00K | -$2.83 Million | 566.43x | N/A |
| 2017 | $101.85 Million | $239.00K | -$4.96 Million | 426.17x | N/A |
| 2018 | $78.81 Million | $318.00K | -$4.15 Million | 247.83x | N/A |
| 2019 | $62.03 Million | $530.00K | -$5.79 Million | 117.03x | N/A |
| 2020 | $16.63 Million | $623.00K | -$4.33 Million | 26.69x | N/A |
| 2021 | $22.63 Million | $1.70 Million | -$14.28 Million | 13.35x | N/A |
| 2022 | $5.48 Million | $752.00K | -$5.45 Million | 7.29x | N/A |
| 2023 | $1.25 Million | $2.28 Million | -$3.71 Million | 0.55x | N/A |
| 2024 | $642.03K | $2.56 Million | -$3.71 Million | 0.25x | N/A |
Competitor Companies of NAOV by Market Capitalization
Companies near NanoVibronix Inc in the global market cap rankings as of March 19, 2026.
Key companies related to NanoVibronix Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #84 globally with a market cap of $187.53 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #151 globally with a market cap of $119.88 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #170 globally with a market cap of $111.60 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #183 globally with a market cap of $105.38 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #84 | Abbott Laboratories | NYSE:ABT | $187.53 Billion | $108.49 |
| #151 | Stryker Corporation | NYSE:SYK | $119.88 Billion | $345.81 |
| #170 | Medtronic PLC | NYSE:MDT | $111.60 Billion | $87.21 |
| #183 | Boston Scientific Corp | NYSE:BSX | $105.38 Billion | $71.28 |
NanoVibronix Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, NanoVibronix Inc's market cap moved from $105.77 Million to $ 4.46 Million, with a yearly change of -26.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.46 Million | +594.92% |
| 2024 | $642.03K | -48.70% |
| 2023 | $1.25 Million | -77.18% |
| 2022 | $5.48 Million | -75.77% |
| 2021 | $22.63 Million | +36.11% |
| 2020 | $16.63 Million | -73.19% |
| 2019 | $62.03 Million | -21.30% |
| 2018 | $78.81 Million | -22.62% |
| 2017 | $101.85 Million | -21.48% |
| 2016 | $129.71 Million | +22.63% |
| 2015 | $105.77 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of NanoVibronix Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.46 Million USD |
| MoneyControl | $4.46 Million USD |
| MarketWatch | $4.46 Million USD |
| marketcap.company | $4.46 Million USD |
| Reuters | $4.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.